MedTrace Logo

Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.

NCT05340634 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-04-28

No results posted yet for this study

Summary

Evaluate the efficacy of the combination of antioxidants ALA, NAC, Vit. B6 and SAMe as a dietary supplement, in the improvement of metabolic and endocrine parameters and clinical manifestations of PCOS.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DIETARY_SUPPLEMENT

Metionac

Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months

DRUG

Oral contraceptive

Drospirenone 4 mg once a day

Sponsors & Collaborators

  • Grupo CINUSA (Centros de Investigación en Nutrición y Salud S.L.)

    collaborator UNKNOWN

  • Margan Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2022-02-02
Completion
2022-02-02

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05340634 on ClinicalTrials.gov